Last reviewed · How we verify
FDA Fast Track Designation explained
Eligibility
A drug qualifies for Fast Track if it treats a serious or life-threatening condition AND it fills an unmet medical need. "Serious" is broadly construed — it includes any condition with substantial impact on day-to-day functioning. "Unmet medical need" can be satisfied by demonstrating advantage over existing therapy (efficacy, safety, tolerability, route of administration). Sponsors apply with preclinical or early Phase 1 data.
Benefits
(1) Earlier + more frequent FDA meetings during development; (2) Eligibility for rolling NDA/BLA review — submit modules as ready; (3) Eligibility for Priority Review (6-month vs 10-month review clock); (4) Eligibility for Accelerated Approval based on surrogate endpoint; (5) Less stringent confirmation requirements vs Breakthrough Therapy.
Fast Track vs Breakthrough Therapy
Fast Track is broader and earlier — pre-clinical evidence of activity is enough. Breakthrough Therapy requires clinical evidence of substantial improvement. About 40% of approved drugs hold Fast Track; only ~30% hold Breakthrough. The two can be stacked.
Statistics
The FDA grants ~60-80 Fast Track designations per year. ~70% of Fast Track designations eventually reach approval (vs ~12-14% for unselected pipeline drugs). The boost comes from selection effects (drugs serious enough to qualify are inherently more likely to succeed) plus the actual development benefits.
FAQ
Can a drug hold both Fast Track + Breakthrough Therapy?
Yes. The two are complementary. Sponsors typically apply for Fast Track first (lower bar), then upgrade to Breakthrough Therapy once Phase 1/early Phase 2 efficacy data is available.
Does Fast Track guarantee approval?
No — it accelerates development but doesn't change the safety + efficacy bar. ~30% of Fast Track drugs ultimately don't reach approval.
How is Fast Track different from Priority Review?
Fast Track is a designation that applies throughout development. Priority Review is specifically about the FDA review window (6 months instead of 10). Fast Track makes you eligible for Priority Review but doesn't automatically grant it.